Genetic control of susceptibility to spontaneous testicular germ cell tumors in mice

APMIS

Volumn 111, Issue 1, 2003, Pages 184-191

  Lam, Man Yee Josephine ^a   Nadeau, Joseph H ^a,b   Skakkebœk, Niels ^c   Lam, Josephine ^c   Von Eyben, Finn Edler ^c   Page, David ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c NONE

Author keywords

Chromosome substitution strains; Mice; Sensitized polygenic trait analysis; Testicular germ cell tumors

Indexed keywords

AGE DISTRIBUTION; CANCER GENETICS; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CARCINOMA IN SITU; CHROMOSOME 19; CHROMOSOME SUBSTITUTION; CONFERENCE PAPER; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; GENETIC ANALYSIS; GENETIC ENGINEERING; GENETIC LINKAGE; GENETIC REGULATION; GERM CELL TUMOR; INBRED STRAIN; MULTIFACTORIAL INHERITANCE; NON SEMINOMATOUS GERMINOMA; NONHUMAN; ONCOGENE; PRIMORDIAL GERM CELL; PRIORITY JOURNAL; SEMINOMA; TER GENE; TERATOCARCINOMA; TERATOMA; TRP 53 GENE; YOLK SAC TUMOR;

ANIMALS; CHROMOSOMES, MAMMALIAN; DISEASE MODELS, ANIMAL; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GERMINOMA; MALE; MICE; MUTATION; TESTICULAR NEOPLASMS;

EID: 0038222518     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0463.2003.11101221.x     Document Type: Conference Paper

References (45)

1. Bishop DT. Candidate regions for testicular cancer susceptibility genes. The International Testicular Cancer Linkage Consortium. APMIS 1998;106:64-70; discussion 71-2.
2. Buetow Epidemiology of testicular cancer. Epidemiologic Reviews 1995;17:433-49.
3. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997;337:242-53.
4. Vaughn DJ, Gignac GA, Meadows AT. Long-term medical care of testicular cancer survivors. Ann Intern Med 2002;136:463-70.
5. Rapley EA, Crockford GP, Teare D, Biggs P, Seal S, Barfoot R, et al. Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet 2000;24:197-200.
6. Forman D, Oliver RT, Brett AR, Marsh SG, Moses JH, Bodmer JG, et al. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br J Cancer 1992;65:255-62.
7. Lindelof B, Eklund G. Analysis of hereditary component of cancer by use of a familial index by site. Lancet 2001;358:1696-8.
8. Leahy MG, Tonks S, Moses JH, Brett AR, Huddart R, Forman D, et al. Candidate regions for a testicular cancer susceptibility gene. Hum Mol Genet 1995;4:1551-5.
9. Nicholson PW, Harland SJ. Inheritance and testicular cancer. Br J Cancer 1995;71:421-6.
10. Rodriguez E, Mathew S, Reuter V, Ilson DH, Bosl GJ, Chaganti RS. Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res 1992;52:2285-91.
11. Vos A, Oosterhuis JW, de Jong B, Buist J, Schraffordt Koops H. Cytogenetics of carcinoma in situ of the testis. Cancer Genet Cytogenet 1990;46:75-81.
12. Looijenga LH, Verkerk AJ, Dekker MC, van Gurp RJ, Gillis AJ, Oosterhuis JW Genomic imprinting in testicular germ cell tumours. APMIS 1998;106:187-95; discussion 196-7.
13. Rajpert-De Meyts E, Kvist M, Skakkebaek NE. Heterogeneity of expression of immunohistochemical tumor markers in testicular carcinoma in situ: pathogenetic relevance. Virchows Arch 1996;428:133-9.
14. Stevens LC, Hummel KP. A description of spontaneous congenital testicular teratomas in strain 129 mice. J Natl Cancer Inst 1957;18:719-31.
15. Stevens LC, Mackensen JA. Genetic and Environmental Influences on Teratocarcinogenesis in Mice. J Natl Cancer Inst 1961;27:443-53.
16. Stevens LC. Origin of testicular teratomas from primordial germ cells in mice. J Natl Cancer Inst 1967;38:549-52.
17. Molyneaux KA, Stallock J, Schaible K, Wylie C. Time-lapse analysis of living mouse germ cell migration. Dev Biol 2001;240:488-98.
18. Donovan PJ, de Miguel M, Cheng L, Resnick JL. Primordial germ cells, stem cells and testicular cancer. APMIS 1998;106:134-41.
19. Lin H. The tao of stem cells in the germline. Annu Rev Genet 1997;31:455-91.
20. Stevens LC. Testicular teratomas in fetal mice. J Natl Cancer Inst 1962;28:247-67.
21. Stevens LC. The biology of teratomas. Adv Morphog 1967;6:1-31.
22. Silvers WK. The Coat Colors of Mice. New York: Springer-Verlag, 1979.
23. Copeland NG, Gilbert DJ, Cho BC, Donovan PJ, Jenkins NA, Cosman D, et al. Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 1990;63:175-83.
24. Bedell MA, Cleveland LS, O'Sullivan TN, Copeland NG, Jenkins NA. Deletion and interallelic complementation analysis of Steel mutant mice. Genetics 1996;142:935-44.
25. Chabot B, Stephenson D, Chapman V, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988;335:88-9.
26. Dolci S, Williams DE, Ernst MK, Resnick JL, Brannan CI, Lock LF, et al. Requirement for mast cell growth factor for primordial germ cell survival in culture. Nature 1991;352:809-11.
27. Noguchi T, Noguchi M. A recessive mutation (ter) causing germ cell deficiency and a high incidence of congenital testicular teratomas in 129/Sv-ter mice. J Natl Cancer Inst 1985;75:385-92.
28. Sakurai T, Iguchi T, Moriwaki K, Noguchi M. The ter mutation first causes primordialgerm cell deficiency in ter/ter mouse embryos at 8 days of gestation. Develop Growth Differ 1995;37: 293-302.
29. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
30. Harvey M, McArthur MJ, Montgomery CA Jr, Bradley A, Donehower LA Genetic background alters the spectrum of tumors that develop in p53-deficient mice. Faseb J 1993;7:938-43.
31. Cuenot L. La loi de Mendel et l'hereditie de la pigmentation chez la souris. Arch Zool Exp Gen 1902;10:26-30.
32. Dickerson G, Gowen J. Science 1947;105:496-8.
33. Fenton P, Chase H. Proc Soc Exp Biol 1951;77:420-2.
34. Carpenter K, Mayer J. Am J Physiol 1976;193:499-504.
35. Plocher T, Powley T. Metabolism 1976;25:593-602.
36. Michaud EJ, Bultman SJ, Klebig ML, van Vugt MJ, Stubbs LJ, Russell LB, et al. A molecular model for the genetic and phenotypic characteristics of the mouse lethal yellow (Ay) mutation. Proc Natl Acad Sci U S A 1994;91:2562-6.
37. Eaton G, Green M. Giant cell differentiation and lethality of homozygous yellow mouse embryos. Genetics 1963;34:155-61.
38. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995;378:203-6.
39. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 2001;29:92-5.
40. Matin A, Nadeau JH. Sensitized polygenic trait analysis. Trends Genet 2001;17:727-31.
41. Collin GB, Asada Y, Varnum DS, Nadeau JH. DNA pooling as a quick method for finding candidate linkages in multigenic trait analysis: an example involving susceptibility to germ cell tumors. Mamm Genome 1996;7:68-70.
42. Matin A, Collin GB, Asada Y, Varnum D, Nadeau JH. Susceptibility to testicular germ-cell tumours in a 129.MOLF-Chr 19 chromosome substitution strain. Nat Genet 1999;23:237-40.
43. Hartley AL, Birch JM, Kelsey AM, Marsden HB, Harris M, Teare MD. Are germ cell tumors part of the Li-Fraumeni cancer family syndrome? Cancer Genet Cytogenet 1989;42:221-6.
44. Malkin D, Li FP, Strong LC Faumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
45. Youngren KK, Nadeau JH, Matin A. Testicular cancer susceptibility in the 129. MOLF-Chr19 mouse strains: additive effects, gene interactions, and epigenetic modifications. Hum Mol Genet 2003;12:389-98.